A number of other equities analysts also recently commented on the company. Stifel Nicolaus restated a “hold” rating and issued a $24.00 target price on shares of Aimmune Therapeutics in a research note on Sunday, August 18th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 20th. Roth Capital assumed coverage on Aimmune Therapeutics in a research report on Friday, July 12th. They set a “buy” rating and a $45.00 price objective for the company. Royal Bank of Canada lowered their price objective on Aimmune Therapeutics to $50.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Finally, Wedbush set a $79.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $41.38.
NASDAQ:AIMT opened at $22.06 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.80 and a current ratio of 5.80. Aimmune Therapeutics has a one year low of $16.95 and a one year high of $36.12. The stock has a 50-day simple moving average of $19.94 and a 200 day simple moving average of $20.82. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -6.01 and a beta of -0.09.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.08). During the same quarter last year, the business earned ($0.91) EPS. On average, equities research analysts forecast that Aimmune Therapeutics will post -4 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in AIMT. Cable Hill Partners LLC boosted its position in Aimmune Therapeutics by 81.7% during the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 500 shares during the period. Manchester Capital Management LLC bought a new stake in Aimmune Therapeutics during the first quarter worth approximately $27,000. Pearl River Capital LLC acquired a new stake in Aimmune Therapeutics in the first quarter worth approximately $28,000. Marshall Wace North America L.P. acquired a new stake in Aimmune Therapeutics in the first quarter worth approximately $32,000. Finally, Aperio Group LLC acquired a new stake in Aimmune Therapeutics in the second quarter worth approximately $76,000. 78.06% of the stock is currently owned by hedge funds and other institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: Penny Stocks, What You Need To Know
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.